Alerts will be sent to your verified email
Verify Email
FDC
|
FDC
|
Strides Pharma Scien
|
Marksans Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
Domestic Sales Growth - YoY
|
5.1 % | n/a | n/a |
|
R&D as a % of Total Sales
|
2.06 % | 1.84 % | 2.2 % |
|
Financials
|
|||
|
5 yr Average ROE
|
13.66 % | 23.7 % | 17.57 % |
|
5yr average Equity Multiplier
|
1.57 | 2.62 | 1.33 |
|
5yr Average Asset Turnover Ratio
|
0.54 | 0.6 | 0.9 |
|
5yr Avg Net Profit Margin
|
16.24 % | 12.9 % | 14.56 % |
|
Price to Book
|
3.4 | 3.02 | 4.13 |
|
P/E
|
29.06 | 21.25 | 26.74 |
|
5yr Avg Cash Conversion Cycle
|
-14.0 Days | -51.45 Days | 71.65 Days |
|
Inventory Days
|
59.23 Days | 69.05 Days | 89.77 Days |
|
Days Receivable
|
21.91 Days | 60.35 Days | 65.99 Days |
|
Days Payable
|
86.54 Days | 225.58 Days | 88.81 Days |
|
5yr Average Interest Coverage Ratio
|
93.3 | 0.72 | 38.03 |
|
5yr Avg ROCE
|
14.95 % | 10.5 % | 21.95 % |
|
5yr Avg Operating Profit Margin
|
18.97 % | 12.17 % | 20.32 % |
|
5 yr average Debt to Equity
|
0.0 | 1.01 | 0.02 |
|
5yr CAGR Net Profit
|
4.94 % | 68.01 % | 10.03 % |
|
5yr Average Return on Assets
|
8.73 % | 10.97 % | 13.19 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
69.66 % | 28.3 % | 43.87 % |
|
Share Pledged by Promoters
|
0.0 | 50.1 % | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.16 % | -2.07 % | -4.38 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
1.1 % | -0.99 % | 2.6 % |
|
FDC
|
Strides Pharma Scien
|
Marksans Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
-
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|